Literature DB >> 1338717

Differential action of (-)-baclofen on the primary afferent depolarization produced by segmental and descending inputs.

J Quevedo1, J R Eguibar, I Jiménez, P Rudomin.   

Abstract

The purpose of the present series of experiments was to analyze, in anesthetized and paralyzed cats, the effects of (-)-baclofen and picrotoxin on the primary afferent depolarization (PAD) generated in single Ib afferent fibers by either intraspinal microstimulation or stimulation of the segmental and descending pathways. PAD was estimated by recording dorsal root potentials and by measuring the changes in the intraspinal activation threshold of single Ib muscle afferent fibers. The PAD elicited by stimulation of group I muscle or cutaneous afferents was readily depressed and often abolished 20-40 min after the intravenous injection of 1-2 mg/kg (-)-baclofen. In contrast, the same amounts of (-)-baclofen produced a relatively small depression of the PAD elicited by stimulation of the brainstem reticular formation (RF). The monosynaptic PAD produced in single Ib fibers by intraspinal microstimulation within the intermediate nucleus was depressed and sometimes abolished following the i.v. injections of 1-2 mg/kg (-)-baclofen. Twenty to forty minutes after the i.v. injection of picrotoxin (0.5-1 mg/kg), there was a strong depression of the PAD elicited by stimulation of muscle and cutaneous afferents as well as of the PAD produced by stimulation of the RF and the PAD produced by intraspinal microstimulation. The results obtained suggest that, in addition to its action on primary afferents, (-)-baclofen may depress impulse activity and/or transmitter release in a population of last-order GABAergic interneurons that mediate the PAD of Ib fibers. The existence of GABAb autoreceptors in last-order interneurons mediating the PAD may function as a self-limiting mechanism controlling the synaptic efficacy of these interneurons.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1338717     DOI: 10.1007/bf00230011

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  35 in total

1.  PRIMARY AFFERENT DEPOLARIZATION EVOKED FROM THE SENSORIMOTOR CORTEX.

Authors:  D CARPENTER; A LUNDBERG; U NORRSELL
Journal:  Acta Physiol Scand       Date:  1963 Sep-Oct

2.  Depolarization of central terminals of Group I afferent fibres from muscle.

Authors:  J C Eccles; F Magni; W D Willis
Journal:  J Physiol       Date:  1962-01       Impact factor: 5.182

Review 3.  Modulation of neurotransmitter release by presynaptic autoreceptors.

Authors:  K Starke; M Göthert; H Kilbinger
Journal:  Physiol Rev       Date:  1989-07       Impact factor: 37.312

4.  Short-term effects of intrathecal baclofen in spasticity.

Authors:  M L Latash; R D Penn; D M Corcos; G L Gottlieb
Journal:  Exp Neurol       Date:  1989-02       Impact factor: 5.330

5.  Modifications of presynaptic inhibition of various origins by local application of convulsant drugs on cat's spinal cord.

Authors:  J M Benoist; J M Besson; J R Boissier
Journal:  Brain Res       Date:  1974-05-10       Impact factor: 3.252

6.  Sites of action of segmental and descending control of transmission on pathways mediating PAD of Ia- and Ib-afferent fibers in cat spinal cord.

Authors:  P Rudomín; I Jiménez; M Solodkin; S Dueñas
Journal:  J Neurophysiol       Date:  1983-10       Impact factor: 2.714

7.  Mechanisms involved in presynaptic depolarization of group I and rubrospinal fibers in cat spinal cord.

Authors:  P Rudomín; I Engberg; I Jiménez
Journal:  J Neurophysiol       Date:  1981-09       Impact factor: 2.714

8.  Effects of baclofen on spinal neurones of cats.

Authors:  M Kato; U Waldmann; S Murakami
Journal:  Neuropharmacology       Date:  1978-10       Impact factor: 5.250

9.  Reduction by baclofen of monosynaptic EPSPs in lumbosacral motoneurones of the anaesthetized cat.

Authors:  F R Edwards; P J Harrison; J J Jack; D M Kullmann
Journal:  J Physiol       Date:  1989-09       Impact factor: 5.182

10.  Selective effects of (-)-baclofen on spinal synaptic transmission in the cat.

Authors:  D R Curtis; D Lodge; J C Bornstein; M J Peet
Journal:  Exp Brain Res       Date:  1981       Impact factor: 1.972

View more
  8 in total

1.  Disynaptic vestibulospinal and reticulospinal excitation in cat lumbosacral motoneurons: modulation during fictive locomotion.

Authors:  J P Gossard; M K Floeter; A M Degtyarenko; E S Simon; R E Burke
Journal:  Exp Brain Res       Date:  1996-05       Impact factor: 1.972

Review 2.  Invertebrate presynaptic inhibition and motor control.

Authors:  F Clarac; D Cattaert
Journal:  Exp Brain Res       Date:  1996-11       Impact factor: 1.972

3.  Subcortical control of precision grip after human spinal cord injury.

Authors:  Karen L Bunday; Toshiki Tazoe; John C Rothwell; Monica A Perez
Journal:  J Neurosci       Date:  2014-05-21       Impact factor: 6.167

Review 4.  Synaptic control of motoneuronal excitability.

Authors:  J C Rekling; G D Funk; D A Bayliss; X W Dong; J L Feldman
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

5.  Raphe magnus and reticulospinal actions on primary afferent depolarization of group I muscle afferents in the cat.

Authors:  J Quevedo; J R Eguibar; I Jiménez; P Rudomin
Journal:  J Physiol       Date:  1995-02-01       Impact factor: 5.182

6.  Selective effects of baclofen on use-dependent modulation of GABAB inhibition after tetraplegia.

Authors:  Melissa D Barry; Karen L Bunday; Robert Chen; Monica A Perez
Journal:  J Neurosci       Date:  2013-07-31       Impact factor: 6.167

7.  Low frequency depression of H-reflexes in humans with acute and chronic spinal-cord injury.

Authors:  S Schindler-Ivens; R K Shields
Journal:  Exp Brain Res       Date:  2000-07       Impact factor: 1.972

8.  Effect of excitatory and inhibitory agents and a glial inhibitor on optically-recorded primary-afferent excitation.

Authors:  Hiroshi Ikeda; Takaki Kiritoshi; Kazuyuki Murase
Journal:  Mol Pain       Date:  2008-09-26       Impact factor: 3.395

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.